JP2012522989A - インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法 - Google Patents

インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法 Download PDF

Info

Publication number
JP2012522989A
JP2012522989A JP2012503660A JP2012503660A JP2012522989A JP 2012522989 A JP2012522989 A JP 2012522989A JP 2012503660 A JP2012503660 A JP 2012503660A JP 2012503660 A JP2012503660 A JP 2012503660A JP 2012522989 A JP2012522989 A JP 2012522989A
Authority
JP
Japan
Prior art keywords
acid
subject
biomarkers
level
insulin resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012503660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522989A5 (enExample
Inventor
フー、ユン、フ
チリラ、コスタル
アレクサンダー、ダニー
ミルバーン、マイケル
ミッチェル、マシュー、ダブリュー．
ガル、ウォルター
ロートン、ケイ、エイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of JP2012522989A publication Critical patent/JP2012522989A/ja
Publication of JP2012522989A5 publication Critical patent/JP2012522989A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012503660A 2009-03-31 2010-03-31 インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法 Pending JP2012522989A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16533609P 2009-03-31 2009-03-31
US61/165,336 2009-03-31
US16657209P 2009-04-03 2009-04-03
US61/166,572 2009-04-03
PCT/US2010/029399 WO2010114897A1 (en) 2009-03-31 2010-03-31 Biomarkers related to insulin resistance and methods using the same

Publications (2)

Publication Number Publication Date
JP2012522989A true JP2012522989A (ja) 2012-09-27
JP2012522989A5 JP2012522989A5 (enExample) 2013-01-17

Family

ID=42828685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012503660A Pending JP2012522989A (ja) 2009-03-31 2010-03-31 インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法

Country Status (6)

Country Link
US (1) US20120122981A1 (enExample)
EP (1) EP2414535A4 (enExample)
JP (1) JP2012522989A (enExample)
CN (1) CN102449161A (enExample)
BR (1) BRPI1013387A2 (enExample)
WO (1) WO2010114897A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015129777A (ja) * 2015-04-15 2015-07-16 ライオン株式会社 脂質異常症の判定方法
JP2016509222A (ja) * 2013-01-31 2016-03-24 メタボロン，インコーポレイテッド インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法
JP2019500619A (ja) * 2015-10-18 2019-01-10 ジア，ウェイ 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置
JP2019502109A (ja) * 2015-12-17 2019-01-24 マース インコーポレーテッドＭａｒｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 脂質の代謝産物を調節するための食品および方法
JP2020531800A (ja) * 2017-08-17 2020-11-05 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 思春期前の小児期前糖尿病のマーカー
JP2021193379A (ja) * 2014-04-08 2021-12-23 メタボルン インコーポレーティッド 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
JP2022501579A (ja) * 2018-09-27 2022-01-06 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 小児期及び若年成人期においてインスリン抵抗性を発症するリスクについてのマーカー

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172775A4 (en) * 2007-06-25 2010-12-01 Ajinomoto Kk METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION
BRPI0815095B1 (pt) * 2007-07-17 2021-04-13 Metabolon, Inc Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo
US10215765B2 (en) 2010-09-15 2019-02-26 Quest Diagnostics Investments Incorporated Detection of vitamins A and E by tandem mass spectrometry
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
KR101303825B1 (ko) * 2011-06-02 2013-09-05 연세대학교 산학협력단 혈장 대사체를 이용한 제2형 당뇨병 진단 키트
JP6260275B2 (ja) 2011-06-30 2018-01-17 味の素株式会社 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置
JP6158186B2 (ja) * 2011-09-14 2017-07-05 メタボロン，インコーポレイテッド インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
EP2642295A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing
EP2642293A1 (en) 2012-03-22 2013-09-25 Nestec S.A. 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) * 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
WO2014026991A1 (en) * 2012-08-13 2014-02-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Biomarkers for type 2 diabetes
US20140324460A1 (en) * 2012-09-26 2014-10-30 Health Diagnostic Laboratory, Inc. Method for determining and managing total cardiodiabetes risk
WO2014105858A1 (en) 2012-12-26 2014-07-03 Quest Diagnostics Investments Incorporated C peptide detection by mass spectrometry
US10191032B2 (en) 2013-01-11 2019-01-29 True Health Ip Llc Method of detection and treatment of clinically significant post-prandial hyperglycemia in normoglycemic patients
US20140278121A1 (en) * 2013-03-13 2014-09-18 Robust for Life, Inc. Systems and methods for network-based calculation and reporting of metabolic risk
US10772554B2 (en) * 2013-09-04 2020-09-15 Joseph Michael Lawless Kelly Methods and systems for the detection of disease
JP6051257B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法
CN106093430A (zh) * 2016-06-06 2016-11-09 上海阿趣生物科技有限公司 可用于检测糖尿病的标志物及其用途
CN108318573B (zh) * 2016-08-16 2020-11-13 北京毅新博创生物科技有限公司 检测胰岛素抵抗的质谱模型的制备方法
CN106442770B (zh) * 2016-09-05 2019-01-18 南京医科大学 与特发性男性不育相关的精浆代谢小分子标志物及其检测方法和应用
CN106908605B (zh) * 2017-01-22 2019-02-22 中国人民解放军军事医学科学院基础医学研究所 eLtaS蛋白作为预防和治疗胰岛素抵抗相关疾病的药物靶点的应用
CN108623655B (zh) * 2018-05-15 2020-09-01 浙江省农业科学院 改善胰岛素抵抗的二肽el及其用途
CN109298084A (zh) * 2018-07-23 2019-02-01 上海市东方医院 用于检测血清或者血浆中油酸浓度的试剂盒及其制备方法和应用
CN110887808A (zh) * 2019-10-28 2020-03-17 广东省测试分析研究所（中国广州分析测试中心） 一种红外光谱技术快速检测阿卡波糖发酵过程中的糖源含量的方法
CN112903885B (zh) * 2019-12-03 2022-05-06 中国科学院大连化学物理研究所 一种筛查糖尿病的联合型代谢标志物的应用及其试剂盒
CN213980949U (zh) 2020-08-27 2021-08-17 康明斯电力公司 用于发电机组的系统
CN112461986B (zh) * 2021-02-03 2021-06-08 首都医科大学附属北京友谊医院 一种用于评估空腹血糖受损和2型糖尿病患病风险的整合生物标志物体系
EP3922990B1 (en) 2021-03-28 2024-05-08 MS Ekspert Sp. z o.o. System for automatic changing and sealing of disposable chromatographic columns in high-performance liquid chromatography; measurement method and its application in the analysis of biomarker of rare disease
CN113929762B (zh) * 2021-12-16 2022-04-26 清华大学 3-羟基丁酰化和/或3-羟基戊酰化修饰胰岛素及其应用
CN117159717A (zh) * 2023-09-28 2023-12-05 广东省人民医院 Slc25a33在制备预防或治疗葡萄糖代谢相关疾病的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106054A2 (en) * 2007-02-22 2008-09-04 Lipomics Technologies, Inc. Metabolic markers of diabetic conditions and methods of use thereof
WO2009014639A2 (en) * 2007-07-17 2009-01-29 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0825258A4 (en) * 1996-02-20 2001-12-05 Kyowa Hakko Kogyo Kk METHOD OF DETERMINING 1,5-ANHYDROGLUCITOL
US20030092028A1 (en) * 2001-06-01 2003-05-15 Yuanhong Ma Methods and Reagents For Diagnosis and Treatment of Insulin Resistance and Related Condition
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106054A2 (en) * 2007-02-22 2008-09-04 Lipomics Technologies, Inc. Metabolic markers of diabetic conditions and methods of use thereof
WO2009014639A2 (en) * 2007-07-17 2009-01-29 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013060272; 海老沼　宏幸、三宅　紀子、三井田　孝肥: '「肥満関連健康障害のバイオマーカーとしての多量体アディポネクチン」' 臨床化学 Ｖｏｌ．　３７，　Ｎｏ．　３, 200807, ｐ．　２４５-２５１, 日本臨床化学会 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509222A (ja) * 2013-01-31 2016-03-24 メタボロン，インコーポレイテッド インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法
JP2021193379A (ja) * 2014-04-08 2021-12-23 メタボルン インコーポレーティッド 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
JP2023175853A (ja) * 2014-04-08 2023-12-12 メタボルン インコーポレーティッド 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
JP2015129777A (ja) * 2015-04-15 2015-07-16 ライオン株式会社 脂質異常症の判定方法
JP2019500619A (ja) * 2015-10-18 2019-01-10 ジア，ウェイ 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置
JP2019502109A (ja) * 2015-12-17 2019-01-24 マース インコーポレーテッドＭａｒｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 脂質の代謝産物を調節するための食品および方法
JP2023062110A (ja) * 2015-12-17 2023-05-02 マース インコーポレーテッド 脂質の代謝産物を調節するための食品および方法
JP2020531800A (ja) * 2017-08-17 2020-11-05 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 思春期前の小児期前糖尿病のマーカー
JP7197555B2 (ja) 2017-08-17 2022-12-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 思春期前の小児期前糖尿病のマーカー
JP2022501579A (ja) * 2018-09-27 2022-01-06 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 小児期及び若年成人期においてインスリン抵抗性を発症するリスクについてのマーカー
JP2024095812A (ja) * 2018-09-27 2024-07-10 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 小児期及び若年成人期においてインスリン抵抗性を発症するリスクについてのマーカー

Also Published As

Publication number Publication date
EP2414535A1 (en) 2012-02-08
EP2414535A4 (en) 2012-12-26
US20120122981A1 (en) 2012-05-17
CN102449161A (zh) 2012-05-09
BRPI1013387A2 (pt) 2019-04-16
WO2010114897A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
JP2012522989A (ja) インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法
US10175233B2 (en) Biomarkers for cardiovascular diseases and methods using the same
US9910047B2 (en) Biomarkers related to insulin resistance progression and methods using the same
JP6158186B2 (ja) インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
AU2014216035B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
AU2016206265B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
HK1142636B (en) Biomarkers for pre-diabetes and methods using the same
HK1217516B (en) Biomarkers related to insulin resistance progression and methods using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140718